In 2010, the NIDDK allocated a whopping $640,444,000 to projects in diabetes, endocrinology, and metabolic diseases.The ADA’s research funding in 2010 was $33.5 million...
Category: Research
On October 15th, we will have TEDxDelMar, with seventeen amazing speakers, all talking about what's next in type 1 diabetes...
JDRF-funded researchers in collaboration with Hoffmann-La Roche pharmaceutical company have discovered a protein that regulates beta cell growth and a chemical compound that stimulates it.
The discovery represents a significant advance in identifying a new drug target for beta cell regeneration...
PositiveID announced it has successfully completed Phase II testing of its GlucoChip™, a glucose-sensing microchip for diabetes patients. In Phase II, the Company, in conjunction with its development partner RECEPTORS LLC, created and demonstrated a stable and reproducible, closed-cycle...
Diamyd Medical announced it has shifted its focus from the development of the diabetes therapy Diamyd® to the the development of drug candidates for the treatment of chronic pain....
Obesity is the main culprit in the worldwide avalanche of type 2 diabetes. But how excess weight drives insulin resistance, the condition that may lead to the disease, is only partly understood. Scientists at Joslin Diabetes Center now have uncovered a new way in which obesity wreaks its havoc, by altering the production of proteins that affect how other proteins are spliced together. Their finding, published in Cell Metabolism, may point toward novel targets for diabetes drugs...
Currently, beta-cell death is very hard to measure...
XOMA announced the first presentation of results from its discovery of two new classes of fully human monoclonal antibodies that activate or sensitize the insulin receptor in vivo, each representing a distinct new therapeutic approach to the treatment of patients with diabetes. The data were presented at the American Diabetes Association 71st Scientific Sessions in San Diego...
Diamyd Medical has suspended dosing in its US Phase III study, DiaPrevent, with the antigen-based therapy Diamyd® following consultation with the US Food and Drug Administration (FDA). Termination follows a blinded review of the efficacy data collected to date in the study as well as the previously reported negative outcome...
The bio artificial pancreas is implanted subcutaneously and oxygen is delivered to the islets via injection...